APRE

$0.00

(

+0.00%

)
Quote details

stock

Aprea Therapeutics Inc

NASDAQ | APRE

1.46

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$8.50M

Market Cap

-

P/E Ratio

-2.3

EPS

$5.01

52 Week High

$1.37

52 Week Low

HEALTHCARE

Sector

APRE Chart

Recent Chart
Price Action

APRE Technicals

Tags:

APRE Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.5M
Total Revenue $1.5M
Cost Of Revenue $22K
Costof Goods And Services Sold $22K
Operating Income -$14M
Selling General And Administrative $6.5M
Research And Development $9.4M
Operating Expenses $16M
Investment Income Net -
Net Interest Income $1.3M
Interest Income $1.3M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $22K
Income Before Tax -$13M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$13M
Comprehensive Income Net Of Tax -
Ebit -$13M
Ebitda -$13M
Net Income -$13M

Revenue & Profitability

Earnings Performance

APRE Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $24M
Total Current Assets $24M
Cash And Cash Equivalents At Carrying Value $23M
Cash And Short Term Investments $23M
Inventory -
Current Net Receivables -
Total Non Current Assets $403K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $726K
Other Non Current Assets -
Total Liabilities $4.7M
Total Current Liabilities $3.4M
Current Accounts Payable $1.4M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $1.3M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $2M
Other Non Current Liabilities -
Total Shareholder Equity $19M
Treasury Stock -
Retained Earnings -$321M
Common Stock $5.5K
Common Stock Shares Outstanding $5.5M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$14M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $22K
Capital Expenditures $15K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$15K
Cashflow From Financing $15M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$13M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.5M
Total Revenue $1.5M
Cost Of Revenue $22K
Costof Goods And Services Sold $22K
Operating Income -$14M
Selling General And Administrative $6.5M
Research And Development $9.4M
Operating Expenses $16M
Investment Income Net -
Net Interest Income $1.3M
Interest Income $1.3M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $22K
Income Before Tax -$13M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$13M
Comprehensive Income Net Of Tax -
Ebit -$13M
Ebitda -$13M
Net Income -$13M

APRE News

APRE Profile

Aprea Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on advancing innovative cancer therapies that aim to reactivate the mutant p53 tumor suppressor protein, a critical pathway in tumor suppression. With a robust pipeline of therapies addressing various cancer types, Aprea is poised to make significant contributions to oncology through its novel approaches. The company’s commitment to enhancing patient outcomes positions it as a noteworthy player in the biopharmaceutical sector, appealing to institutional investors looking for impactful healthcare innovation.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
WOK
-5.22%
$0.08
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
SOFI
-0.49%
$27.98
ONDS
-1.16%
$7.66
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
WOK
-5.22%
$0.08
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
SOFI
-0.49%
$27.98
ONDS
-1.16%
$7.66
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.